Prucalopride — Membership Pricing

Other medications in Digestive Health

• Psyllium
• Rabeprazole
• Senna
• Teduglutide
• Tegaserod
• Ustekinumab
• Vedolizumab
• Adalimumab

About Prucalopride

Struggling with chronic idiopathic constipation (CIC) can significantly impact your daily life. Prucalopride offers a targeted approach to managing this persistent condition, helping to restore regular bowel function. As a member of TheDrugClub, you can access potential savings on medications like prucalopride, making effective treatment more affordable and accessible for you and your family.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Prucalopride is approved for (FDA label)

Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. Prucalopride tablet is a serotonin-4 (5-HT 4 ) receptor agonist indicated for the treatment of chronic idiopathic constipation (CIC) in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 31, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Prucalopride (FDA label)

Prucalopride Tablets: • 1 mg prucalopride: white colored, round shaped, film-coated tablets, debossed with ‘1U’ on one side and plain on other side. • 2 mg prucalopride: pink colored, round shaped, film-coated tablets, debossed with ‘2U’ on one side and plain on other side. Tablets: 1 mg, 2 mg of prucalopride. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 89a7bdb1-e1cd-4986-bab9-a939dc764faa. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Prucalopride (FDA label)

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The data described below represent 2,530 patients (1,251 received prucalopride 2 mg once daily and 1,279 received placebo) with CIC from 6 double-blind, placebo-controlled clinical trials of 12 weeks to 24 weeks in duration.

Source: FDA prescribing information (DailyMed). Set ID: 89a7bdb1-e1cd-4986-bab9-a939dc764faa. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Prucalopride (FDA label)

Prucalopride tablets are contraindicated in patients with: A history of hypersensitivity to prucalopride tablets. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed [see Adverse Reactions (6.2)]. Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum. • Hypersensitivity to prucalopride tablets. ( 4 ) • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 89a7bdb1-e1cd-4986-bab9-a939dc764faa. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Prucalopride (FDA label)

Suicidal Ideation and Behavior : Monitor patients for suicidal ideation and behavior as well as self-injurious ideation and new-onset or worsening of depression. Instruct patients to discontinue prucalopride immediately and contact their healthcare provider if they experience any unusual changes in mood or behavior, or they experience emerging suicidal thoughts or behaviors. ( 5.1 ) 5.1 Suicidal Ideation and Behavior In clinical trials, suicides, suicide attempts, and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting prucalopride [see Adverse Reactions (6.1, 6.2)]. A causal association between treatment with prucalopride and an increased risk of suicidal ideation and behavior has not been established. Monitor all patients treated with prucalopride for new onset or worsening of depression or the emergence of suicidal thoughts and behaviors.

Source: FDA prescribing information (DailyMed). Set ID: 89a7bdb1-e1cd-4986-bab9-a939dc764faa. Label effective date: July 31, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.